By Sheeba M. | April 18, 2026
The Cannabis M&A Wave Is Building Again — and This Time the Targets Look Different
The cannabis industry’s deal-making freeze is thawing. After a 2024-2025 period in which acquisition activity ground to a near-halt amid high interest rates, depressed valuations, and regulatory uncertainty, deal flow is returning to the sector — and the profile of attractive targets has changed in ways that favor a different type of operator than the one that dominated the last M&A wave.
Why the Last Wave Failed — and What That Means Now
The cannabis M&A boom of 2019-2022 was defined by scale at any cost. MSOs raced to accumulate licenses, store counts, and state footprints, often paying 10x, 12x, or even 15x trailing revenue for assets that had not yet proven they could generate sustainable cash flow. When rates rose and capital tightened, those deals came undone. Goodwill write-downs, abandoned integrations, and balance sheet strain followed.
The deals getting done today look different. Buyers — particularly the better-capitalized MSOs with realPath-to-profitability focus — are targeting operators with demonstrated EBITDA, clean regulatory records, and management teams that can be retained through earnouts. Revenue multiple targets have compressed from the mid-teens to the high single digits or low double digits for assets with positive operating income.
For investors, this shift creates an interesting dynamic: the operators most likely to be acquired are precisely those with the strongest underlying fundamentals, which means their stocks may re-rate before a deal is ever announced.
Who’s Buying and What They Want
Curaleaf (CURLF) and Green Thumb Industries (GTBIF) remain the most active strategic buyers, but they are being joined by a new category of financial buyers — cannabis-focused private equity funds that raised capital in 2023-2024 and are now actively deploying it. These funds don’t face the same public market pressures as MSOs and can afford to be patient.
What all buyers share is a preference for operators in high-barrier medical states — Florida, Pennsylvania, Ohio, and Illinois continue to top every acquisition target list. The reasoning is straightforward: limited license states with robust medical programs generate predictable cash flows that are easier to underwrite than adult-use markets with more volatile pricing dynamics.
For holders of operators in those states — particularly those tracking Cresco Labs (CRLBF), Trulieve (TCNNF), or Verano (VRNO) — the M&A tailwind may arrive sooner than expected.
The Regulatory Wild Card
No M&A discussion in cannabis is complete without acknowledging the regulatory wildcard. SAFER Banking Act remains the most frequently cited legislative catalyst for deal activity — its passage would unlock access to traditional banking services and significantly reduce the operational complexity (and cost) of running cash-heavy cannabis operations. That, in turn, would make a broader range of buyers and lenders comfortable engaging with the sector.
While we don’t make legislative predictions, the directional trend in Washington is favorable for cannabis financial reform, and the current Senate dynamics suggest SAFER Banking has a reasonable path forward in 2026. If it passes, expect M&A volume to surge — and for the first time in years, for valuations to reflect the quality of assets rather than the desperation of sellers.
Sources
- Reuters — Cannabis sector M&A coverage
- Bloomberg — MSO financial analysis and deal tracking
- SEC EDGAR — Deal-related regulatory filings
Track cannabis stocks with the Weedstock Real-Time Tracker